Risk Factors Update Summary

• Losses increased from $51 million to $60 million, including a decrease in equity offerings.
• Additional funding of tens of millions required for clinical programs and product development.
• Enhanced cybersecurity measures implemented, including internal server firewall and malware scans several times a day.
• Need for substantial funding to complete clinical programs and trials, especially for VOICE program.
• Cybersecurity policy being drafted to establish standard operating procedures and training for employees.
• Increased financial risk due to Russia-Ukraine and Israel-Hamas wars affecting global conditions.
• Board oversight of cybersecurity risk with a dedicated committee led by the Chief Financial Officer.
• Potential delays in clinical trials due to geopolitical risks and logistical challenges.
• Reliance on third-party manufacturers for product development and clinical trials poses risks.
• Uncertainty in stock price due to potential delisting from Nasdaq non-compliance with listing requirements.